We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+19.62%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$856M
AUM Growth
-$34.3M
Cap. Flow
+$13.7M
Cap. Flow %
1.6%
Top 10 Hldgs %
65.11%
Holding
33
New
7
Increased
9
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$46.5M
2
MRUS
Merus
MRUS
+$10.4M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$10.3M
4
ELVN icon
Enliven Therapeutics
ELVN
+$9.32M
5
VTGN icon
VistaGen Therapeutics
VTGN
+$6.99M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$51.7M
2
CBAY
Cymabay Therapeutics
CBAY
+$22.2M
3
ARWR icon
Arrowhead Research
ARWR
+$21.8M
4
NUVL
Nuvalent
NUVL
+$14.3M
5
KALV
KalVista Pharmaceuticals
KALV
+$2.81M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYZB
26
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$6.41M 0.75%
+288,911
New +$6.07M
APGE icon
27
Apogee Therapeutics
APGE
$10.2B
$5.33M 0.62%
+250,000
New +$5.51M
MRSN
28
DELISTED
Mersana Therapeutics
MRSN
$2.85M 0.33%
+89,775
New +$4.27M
SYRE icon
29
Spyre Therapeutics
SYRE
$8.87B
$1.42M 0.17%
116,324
– –
DBVT
30
DBV Technologies
DBVT
$807M
$126K 0.01%
9,269
– –
ARWR icon
31
Arrowhead Research
ARWR
$12.1B
– –
-610,000
Closed -$21.8M
KALV
32
DELISTED
KalVista Pharmaceuticals
KALV
– –
-312,553
Closed -$2.81M
CBAY
33
DELISTED
Cymabay Therapeutics
CBAY
– –
-2,025,000
Closed -$22.2M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Commodore Capital held 33 positions worth $856M, down 3.9% from $890M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Commodore Capital's Q3 2023 filing shows 7 new, 9 increased, 3 reduced and 3 closed positions. Its largest new stake was Rhythm Pharmaceuticals: 2,075,000 shares worth $47.6M. The largest sale was Akero Therapeutics, an estimated $51.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Commodore Capital's largest Q3 2023 buy was Rhythm Pharmaceuticals: 2,075,000 shares worth $47.6M.
  • Commodore Capital added most to Merus in Q3 2023, an estimated $10.4M increase.
  • Commodore Capital's biggest Q3 2023 reduction was Akero Therapeutics, cutting an estimated $51.7M.
  • Commodore Capital fully exited Cymabay Therapeutics in Q3 2023, selling an estimated $22.2M.
  • Commodore Capital's ten largest holdings make up 65% of its $856M portfolio in Q3 2023.
  • Commodore Capital opened 7 new positions and closed 3 in Q3 2023.
  • Commodore Capital's portfolio value fell 3.9% quarter-over-quarter to $856M.

Based on Commodore Capital's 13F filing for Q3 2023, filed 14 Nov 2023.